GNLX:NASDAQ
Genelux Corp
USD 2,54
0,00%
(0,00) 1D
USD 2,54
0,00% (0,00)
todayPre-market
Closed: 6 Okt., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Mkt. cap
113,16 m
Avg. vol.
270,21 k
Volume
200,00
52-wk high
USD 8,54
52-wk low
USD 2,29
EPS
-USD 0,87
Beta
0,59
Shares outstanding
45,24 m
No. of employees
26
Mkt. cap
113,16 m
Avg. vol.
270,21 k
Volume
200,00
52-wk high
USD 8,54
52-wk low
USD 2,29
EPS
-USD 0,87
Beta
0,59
Shares outstanding
45,24 m
No. of employees
26
News stories
From web sources and news partners
Yahoo Finance
·
33 minute gelede
KQC Quantum, Inc. and Charlton Aria Acquisition Corporation Announce Definitive Business Combination Agreement to Take Korea’s Enterprise Quantum Computing and Quantum-Safe Security Company Public on Nasdaq
www.marketscreener.com
·
20 minute gelede
WISeSat.Space to Ring the Nasdaq Opening Bell on October 9 and Highlight Secure Space Infrastructure Strategy at Convene Quantum Space Security Roundtable
PR Newswire UK
·
8 minute gelede
Snorkel AI Raises $350 Million to Help Push the Frontier: NYSE Content Update
CNBC
·
1 uur gelede
AI trade driving stocks, but questions remain over rest of market
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, Kalifornië, Verenigde State van Amerika
Sector-
Websitegenelux.com